Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Wiam Belkaïd"'
Autor:
Marion Tonneau, Kim Phan, Venkata S. K. Manem, Cecile Low-Kam, Francis Dutil, Suzanne Kazandjian, Davy Vanderweyen, Justin Panasci, Julie Malo, François Coulombe, Andréanne Gagné, Arielle Elkrief, Wiam Belkaïd, Lisa Di Jorio, Michele Orain, Nicole Bouchard, Thierry Muanza, Frank J. Rybicki, Kam Kafi, David Huntsman, Philippe Joubert, Florent Chandelier, Bertrand Routy
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundRecent developments in artificial intelligence suggest that radiomics may represent a promising non-invasive biomarker to predict response to immune checkpoint inhibitors (ICIs). Nevertheless, validation of radiomics algorithms in independe
Externí odkaz:
https://doaj.org/article/1c9b27366e80483d88227a18e19ca975
Autor:
Marion Tonneau, Kim Phan, Cécile Low-Kam, Francis Dutil, Suzanne Kazandjian, Davy Vanderweyen, Justin Panasci, Julie Malo, François Coulombe, Arielle Elkrief, Wiam Belkaïd, Lisa Di Jorio, Michèle Orain, Nicole Bouchard, Thierry Muanza, Kam Kafi, Florent Chandelier, Philippe Joubert, Bertrand Routy
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Antoine Desilets, MD, MSc, Gabryella Pinheiro, PhD, Wiam Belkaid, PhD, Olivier Salko, MD, Julie Malo, Eleyine Zarour, MD, Adeline Jouquan, MSc, Anne-Julie Thibaudeau, MSc, Marc-Antoine Nolin, MSc, John Stagg, PhD, Marie Florescu, MD, Mustapha Tehfe, MD, Normand Blais, MD, MSc, Samer Tabchi, MD, Jean Chalaoui, MD, Philippe Stephenson, MD, Arielle Elkrief, MD, Vincent Quoc-Huy Trinh, MD, MSc, Bertrand Routy, MD, PhD, Moishe Liberman, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100737- (2024)
Introduction: NSCLC is the leading cause of cancer-related mortality. Although immune-checkpoint inhibitors (ICIs) have improved survival in patients with advanced NSCLC, treatment resistance remains a challenge. Cryoactivation, a technique inducing
Externí odkaz:
https://doaj.org/article/f11731bcb8a4444d878c7e52e5ba0d56
Autor:
Khoudia Diop, Benlaïfaoui Myriam, Wiam Belkaïd, Alexis Nolin-Lapalme, Julie Malo, Marion Tonneau, Ponce Mayra, Afnan Al-Saleh, Catalin Mihalcioiu, Ian Watson, Arielle Elkrief, Karla Lee, Meriem Messaoudene, Bertrand Routy, Corentin Richard
Publikováno v:
Cancer Research. 82:3524-3524
The accelerating use of combined immune checkpoint inhibitors (ICI; anti-PD-1 plus anti-CTLA-4 antibodies) enhanced therapeutic responses in various cancers while significantly increasing immune-related adverse events (irAE). The mechanism involved i
Autor:
Sevinj Yolchuyeva, Leyla Ebrahimpour, Marion Tonneau, Fabien Lamaze, Michele Orain, François Coulombe, Julie Malo, Wiam Belkaid, Bertrand Routy, Philippe Joubert, Venkata SK. Manem
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising first-line therapeutics in the management of non-small cell lung cancer (NSCLC). However, only a subset of these patients responds to ICIs, highlighting
Externí odkaz:
https://doaj.org/article/402d9860876a4dd9abb12bb7bde2e5fb
Autor:
Sevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, Fabien Lamaze, Michele Orain, François Coulombe, Julie Malo, Wiam Belkaid, Bertrand Routy, Philippe Joubert, Venkata S. K. Manem
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract With the increasing use of immune checkpoint inhibitors (ICIs), there is an urgent need to identify biomarkers to stratify responders and non-responders using programmed death-ligand (PD-L1) expression, and to predict patient-specific outcom
Externí odkaz:
https://doaj.org/article/fd7837095cb744958b685f0602f90ba3
Autor:
Sevinj Yolchuyeva, PhD, Elena Giacomazzi, MSc, Marion Tonneau, PhD, Fabien Lamaze, PhD, Michele Orain, MT, François Coulombe, MD, Julie Malo, CCRP, Wiam Belkaid, PhD, Bertrand Routy, MD, PhD, Philippe Joubert, MD, PhD, Venkata S.K. Manem, MSc, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100602- (2023)
Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after an initial response. It is still unclear who w
Externí odkaz:
https://doaj.org/article/c5741ef7957448d1a093b10a06ccf5fe
Autor:
Francis Proulx-Rocray, Bertrand Routy, Rami Nassabein, Wiam Belkaid, Danh Tran-Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Tehfe, Normand Blais
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100767- (2023)
Background: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in TP53, STK11 and KEAP1 as well as the NLR showed t
Externí odkaz:
https://doaj.org/article/c40f1a47fa0642819660bfc828e84fc3
Autor:
Marion Tonneau, Alexis Nolin-Lapalme, Suzanne Kazandjian, Edouard Auclin, Justin Panasci, Myriam Benlaifaoui, Mayra Ponce, Afnan Al-Saleh, Wiam Belkaid, Sabrine Naimi, Catalin Mihalcioiu, Ian Watson, Mickael Bouin, Wilson Miller, Marie Hudson, Matthew K. Wong, Rossanna C. Pezo, Simon Turcotte, Karl Bélanger, Rahima Jamal, Paul Oster, Dominique Velin, Corentin Richard, Meriem Messaoudene, Arielle Elkrief, Bertrand Routy
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper ga
Externí odkaz:
https://doaj.org/article/adb7b6925dfe48898a2dcd6d9e30f8ad
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100421- (2021)
Externí odkaz:
https://doaj.org/article/b2d65e60d9e44ef1a790009b2780cfa1